a Novel pre-treatment for the Prevention of Allergic reactions to medicines using a drug-free Carriers

Barenholz Yechezkel, HUJI, School of Medicine - IMRIC, Biochemistry and Molecular Biology


  • Intravenous injection of some liposomal drugs, diagnostic agents, micelles and other lipid-based nanoparticles cause hypersensitivity reactions in up to 45% of patients,

    which appear to be initiated by the complement system (C) of the immune system.
  • Liposomes, Micelles,and other particulate drug carriers which do not carry C inhibitors on their surfaces will activate these hypersensitive reactions.

Our Innovation

a Novel treatment to prevent Allergic reactions to medicines by using a placebo drug-free Carrier, prior to the administration of particulate medicines

Applications for use:

Preventing an allergic reactions to medicines

Key Features

  • Technology specifically inhibits PCM-triggered C3a/C5a receptor-mediated complement activation-related pseudoallergy (CARPA) reactions
  • Toxicology tests for this technology are very simple

The Opportunity

Opportunity to incorporate new technology with minimal regulatory process


Researcher Information            biochemistry.huji.ac.il/faculty_barenholz.asp, research.ekmd.huji.ac.il/researchers.asp?id=166, nanoscience.huji.ac.il/researchers/barenholz.htm



Patent Status

Granted US 9,078,812; Europe 2231190

Contact for more information:

Keren-Or Amar
VP, Business Development, Healthcare
Contact ME: